PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32238050-6 2020 In human CYP2C9 isoform, the Ki value of 21.93 muM (CYP2C9*1), 18.10 muM (CYP2C9*2), 13.12 muM (CYP2C9*3) indicate that there are individual differences in the inhibition of osthole on CYP2C9 activity.We investigated how the indomethacin pharmacokinetics was affected by osthole in SD rat. Indomethacin 225-237 latexin Homo sapiens 47-50 32238050-6 2020 In human CYP2C9 isoform, the Ki value of 21.93 muM (CYP2C9*1), 18.10 muM (CYP2C9*2), 13.12 muM (CYP2C9*3) indicate that there are individual differences in the inhibition of osthole on CYP2C9 activity.We investigated how the indomethacin pharmacokinetics was affected by osthole in SD rat. Indomethacin 225-237 latexin Homo sapiens 69-72 32238050-6 2020 In human CYP2C9 isoform, the Ki value of 21.93 muM (CYP2C9*1), 18.10 muM (CYP2C9*2), 13.12 muM (CYP2C9*3) indicate that there are individual differences in the inhibition of osthole on CYP2C9 activity.We investigated how the indomethacin pharmacokinetics was affected by osthole in SD rat. Indomethacin 225-237 latexin Homo sapiens 69-72 31680861-3 2019 Indomethacin (1 muM) also enhanced CP55940-dependent betaarrestin1 recruitment, cAMP inhibition, ERK1/2 and PLCbeta3 phosphorylation in HEK293A cells expressing hCB1R, but not in cells expressing hCB2R. Indomethacin 0-12 latexin Homo sapiens 16-19 27213322-6 2016 Compared with the positive control drug indomethacin (IC50 = 47.4 muM), compounds 1, 3, 6 and 8 exhibited remarkable anti-inflammatory activities with IC50 values of 5.4, 7.8, 4.0 and 8.9 muM, respectively. Indomethacin 40-52 latexin Homo sapiens 66-69 31544517-4 2021 Compounds 1, 2, 5, 7 and 8 showed potent inhibitory effects, with IC50 values ranging from 32.19 to 48.85 muM, which is better than both the standard drugs indomethacin (154.5 muM) and dexamethasone (56.28 muM). Indomethacin 156-168 latexin Homo sapiens 176-179 31544517-4 2021 Compounds 1, 2, 5, 7 and 8 showed potent inhibitory effects, with IC50 values ranging from 32.19 to 48.85 muM, which is better than both the standard drugs indomethacin (154.5 muM) and dexamethasone (56.28 muM). Indomethacin 156-168 latexin Homo sapiens 176-179 25450393-4 2014 The results showed that indomethacin at high concentration (100 muM) inhibited human tenocyte proliferation in culture medium with 1-10% fetal bovine serum (FBS) in vitro. Indomethacin 24-36 latexin Homo sapiens 64-67 25450393-7 2014 When 50-100 mug/ml lactoferrin was used in combination with 100-200 muM indomethacin, it partially rescued the inhibitory effects of indomethacin on human tenocyte proliferation, viability and collagen formation. Indomethacin 72-84 latexin Homo sapiens 68-71 25450393-7 2014 When 50-100 mug/ml lactoferrin was used in combination with 100-200 muM indomethacin, it partially rescued the inhibitory effects of indomethacin on human tenocyte proliferation, viability and collagen formation. Indomethacin 133-145 latexin Homo sapiens 68-71 18475581-3 1994 Indomethacin (3 muM) enhanced the anti-IgE-induced contraction by 28%. Indomethacin 0-12 latexin Homo sapiens 16-19 23798775-5 2012 After high speed grinding, indomethacin and the mixture had a reduced average particle size of around 5 and 2 mum, respectively, showing a morphological change. Indomethacin 27-39 latexin Homo sapiens 110-113 22361134-4 2012 Furthermore, compound 20 is a selective COX-2 inhibitor in contrast to the reference drug indomethacin that is a potent and selective COX-1 inhibitor (COX-1 IC(50)=0.13 muM; COX-2 IC(50)=6.9 muM, COX-2 SI=0.02). Indomethacin 90-102 latexin Homo sapiens 169-172 21664477-8 2011 Application of a combination of the cyclo-oxygenase (COX) inhibitors indomethacin (30 muM) and ibuprofen (10 muM) did not alter baseline CBF but prevented ciliostimulation by ET-1. Indomethacin 69-81 latexin Homo sapiens 86-89 16331495-3 2006 Indomethacin at 10 muM increased the cytotoxicity of doxorubicin, as well as vincristine in K562/ADR. Indomethacin 0-12 latexin Homo sapiens 19-22 21781914-2 1999 Indomethacin (0.1 muM), which inhibits PGHS and significantly increases leukotriene C(4) production by enhancement of lipoxygenases, enhanced formation of OTA-DNA adducts tenfold. Indomethacin 0-12 latexin Homo sapiens 18-21 21781914-3 1999 At highest dose of 10 muM, indomethacin inhibited all pathways (PGHS and lipoxygenases) and thus prevented OTA-DNA adduct formation. Indomethacin 27-39 latexin Homo sapiens 22-25 21781914-7 1999 After pre-incubation with indomethacin (0.1 muM), further unidentified metabolites were obtained. Indomethacin 26-38 latexin Homo sapiens 44-47 6597721-2 1984 Indometacin proved to be a classical cyclooxygenase inhibitor (strong inhibition of PGE2 and TXB2 before and after pentagastrin stimulation and of PGF-MUM) while carprofen was an atypical inhibitor (weak inhibition of PGE2 before pentagastrin stimulation and no inhibition after, strong inhibition of TXB2 but without influence on PGF-MUM). Indomethacin 0-11 latexin Homo sapiens 151-154 18475517-2 1993 Enzyme activities were completely blocked by indomethacin (5 x 10(-7) M), a PG synthase inhibitor, and actinomycin D (5 muM), an inhibitor of transcription, by binding to DNA. Indomethacin 45-57 latexin Homo sapiens 120-123 3112008-5 1987 Aggregation was partially inhibited by 20 muM [corrected] indomethacin and blocked completely by 1 mg of apyrase, an extracellular ADP hydrolase, per ml. Indomethacin 58-70 latexin Homo sapiens 42-45 7397403-5 1980 Angiotensin II (25 nM) produced a 31 mm Hg increase in perfusion pressure in coronary arteries but indomethacin (20 muM) or sodium meclofenamate (75 muM) reduced this response to 11 and 14 mm Hg, respectively (p < 0.05). Indomethacin 99-111 latexin Homo sapiens 116-119 7274780-5 1981 Also in the presence of indomethacin (90 muM) Haemaccel inhibited aggregation induced by high concentrations of collagen and the primary aggregation induced by ADP and adrenaline, while Plasmion enhanced these aggregations induced by ADP and adrenaline, while Plasmion enhanced these aggregations. Indomethacin 24-36 latexin Homo sapiens 41-44 7397449-4 1980 4 A low concentration of indomethacin (0.17 muM) significantly reduced responsiveness and sensitivity to histamine in stored bronchi but not in fresh bronchi. Indomethacin 25-37 latexin Homo sapiens 44-47 6777398-6 1980 U46619 (1 muM) enhanced vasopressin-stimulated water flow in indomethacin pretreated hemibladders, producing a significant parallel shift (P < 0.001) in the dose-response relationship to submaximal concentrations of vasopressin (0.1-0.6 mU/ml), while not affecting water flow stimulated by supramaximal concentrations of vasopressin (10 mU/ml). Indomethacin 61-73 latexin Homo sapiens 10-13 7397403-5 1980 Angiotensin II (25 nM) produced a 31 mm Hg increase in perfusion pressure in coronary arteries but indomethacin (20 muM) or sodium meclofenamate (75 muM) reduced this response to 11 and 14 mm Hg, respectively (p < 0.05). Indomethacin 99-111 latexin Homo sapiens 149-152 171381-5 1975 Indomethacin, 14-0 muM, prevented the release of PGE-like material in the venous effluent of the spleen elicited by either nerve stimulation or by exogenous noradrenaline. Indomethacin 0-12 latexin Homo sapiens 19-22 291068-7 1979 This effect was not seen with any of five other fatty acids tested and was suppressed by indomethacin (25 muM). Indomethacin 89-101 latexin Homo sapiens 106-109 270668-3 1977 A23187 also induces an antimycin A-insensitive burst in oxygen utilization which is partially blocked by 5 mM aspirin or 10 muM indomethacin. Indomethacin 128-140 latexin Homo sapiens 124-127 176663-9 1976 Indomethacin (14 muM) inhibited PGE2 but stimulated collagenase production whereas dexamethasone (10 nM) inhibited both. Indomethacin 0-12 latexin Homo sapiens 17-20